

Sample Hospital Setting Billing **UB-04**

1 Hospital Name One Hospital Place City, State 00000		2 Pay - To Name Pay - To Address (if different from billing provider in FL1)		3a PAT. CNTL. #	3b MED. REC. #	4 TYPE OF BILL
8 PATIENT NAME		9 PATIENT ADDRESS		5 FED. TAX NO.		
10 BIRTHDATE		11 SEX		12 DATE		13 HR
14 TYPE		15 SRC		16 DHR		17 STAT
18		19		20		21
22		23		24		25
26		27		28		29 ACCT STATE
30		31 OCCURRENCE DATE		32 OCCURRENCE DATE		33 OCCURRENCE DATE
34 OCCURRENCE DATE		35 OCCURRENCE DATE		36 OCCURRENCE SPAN FROM		37 OCCURRENCE SPAN THROUGH
38		39 VALUE CODES		40 VALUE CODES		41 VALUE CODES
42 REV. CD.		43 DESCRIPTION		44 HCPCS / RATE / HIPPS CODE		45 SERV. DATE
46 SERV. UNITS		47 TOTAL CHARGES		48 NON-COVERED CHARGES		49
1	0404	PET/CT, Skull Base to Mid Thigh		78815 - PS		01/14/2021
2	0343	Axumin Fluciclovine F 18, diagnostic, 1 mCi		A9588		01/14/2021
3						
4						
21		22		23		24
25		26		27		28
29		30		31		32
33		34		35		36
37		38		39		40
41		42		43		44
45		46		47		48
49		50		51		52
53		54		55		56
57		58		59		60
61		62		63		64
65		66		67		68
69		70		71		72
73		74		75		76
77		78		79		80
81		82		83		84
85		86		87		88
89		90		91		92
93		94		95		96
97		98		99		

Form Locator 42 (Rev. CD.)
Enter Revenue Code. Possible codes include the following:
0308 PET or **0341** Nuclear Medicine Diagnostic
(providers should verify Revenue Coding with Hospital Finance Dept.)
0343 Diagnostic Radiopharmaceutical

Form Locator 46 (Units of Service)
Enter the number of units based on the HCPCS code descriptor/# mCi injected or payer reporting instructions

Form Locator 44 (HCPCS/Rate/HIPPS Code)
Enter the CPT® or HCPCS code for the procedure, radiopharmaceutical, and drug
78815 PET/CT imaging, skull base to mid-thigh (most common procedure code used for oncologic PET imaging)
A9588 Fluciclovine F 18, diagnostic, 1 mCi

Form Locator 67 (Principal Diagnosis Code)
Enter the ICD-10 code for the principal diagnoses. Possible codes include the following:
R97.21 Rising PSA following prior treatment for malignant neoplasm of the prostate
Z85.46 Personal history of malignant neoplasm of prostate
C61 Malignant neoplasm of prostate
Special note: Do not use the decimal point on the claim form, as it may cause rejection of the claim. Up to 8 additional diagnoses that coexist with the principal diagnosis can be reported in FL 67 A-H.

Blue Earth Diagnostics, Inc. cannot guarantee coverage or reimbursement for Axumin. The existence of billing codes does not guarantee coverage and payment. Payer policies may change without notice. It is the provider's responsibility to determine and submit accurate information on claims. This includes submitting paper codes, modifiers, charges, and invoices for the services that were rendered. It is the provider's responsibility to ensure that all information on a claim is accurate. It is the provider's responsibility to check with the payer to determine whether the information contained on the claim is accurate. It is the responsibility of the provider to document the medical necessity of Axumin in the medical record.

Abbreviations: CPT, current procedural terminology; HCPCS, Healthcare Common Procedure Coding System.
CPT® is a registered trademark of the American Medical Association. CPT Copyright 2021 American Medical Association. All rights reserved.

Please see Axumin Important Safety Information on back.

INDICATION

Axumin[®] (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in $\leq 1\%$ of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Axumin Prescribing Information, also available at www.axumin.com.